These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11588510)

  • 1. Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?
    Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration)
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):158-65. PubMed ID: 11588510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts.
    Phillips AN; Sabin CA; Elford J; Bofill M; Janossy G; Lee CA
    Am J Epidemiol; 1993 Nov; 138(10):870-8. PubMed ID: 7901990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users.
    Prins M; Hernández Aguado IH; Brettle RP; Robertson JR; Broers B; Carré N; Goldberg DJ; Zangerle R; Coutinho RA; van den Hoek A
    AIDS; 1997 Nov; 11(14):1747-56. PubMed ID: 9386810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study.
    Phillips AN; Pezzotti P; Lepri AC; Rezza G
    AIDS; 1994 Sep; 8(9):1299-305. PubMed ID: 7802984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.
    Cozzi Lepri A; Pezzotti P; Dorrucci M; Phillips AN; Rezza G
    BMJ; 1994 Dec; 309(6968):1537-42. PubMed ID: 7819892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.
    Lodi S; Phillips A; Touloumi G; Geskus R; Meyer L; Thiébaut R; Pantazis N; Amo JD; Johnson AM; Babiker A; Porter K;
    Clin Infect Dis; 2011 Oct; 53(8):817-25. PubMed ID: 21921225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression to acquired immunodeficiency syndrome is influenced by CD4 T-lymphocyte count and time since seroconversion.
    Begtrup K; Melbye M; Biggar RJ; Goedert JJ; Knudsen K; Andersen PK
    Am J Epidemiol; 1997 Apr; 145(7):629-35. PubMed ID: 9098180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with progression to AIDS and mortality in a cohort of HIV-infected patients with hemophilia followed up since seroconversion.
    Santagostino E; Gringeri A; Cultraro D; Tradati F; Siracusano L; Marinoni A; Mannucci PM
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):371-80. PubMed ID: 7580830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.
    Touloumi G; Karafoulidou A; Gialeraki A; Katsarou O; Milona I; Kapsimali V; Mandalaki T; Hatzakis A
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):89-97. PubMed ID: 9732075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.
    Maas JJ; Dukers N; Krol A; van Ameijden EJ; van Leeuwen R; Roos MT; de Wolf F; Coutinho RA; Keet IP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):254-9. PubMed ID: 9803967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.
    Babiker A; Darbyshire J; Pezzotti P; Porter K; Rezza G; Walker SA; Beral V; Coutinho R; Del Amo J; Gill N; Lee C; Meyer L; Tyrer F; Dabis F; Thiebaut R; Lawson-Aye S; Boufassa F; Hamouda O; Fischer K; Pezzotti P; Rezza G; Touloumi G; Hatzakis A; Karafoulidou A; Katsarou O; Brettle R; del Romero J; Prins M; van Benthem B; Kirk O; Pederson C; Hernández Aguado I; Pérez-Hoyos S; Eskild A; Bruun JN; Sannes M; Sabin C; Lee C; Johnson AM; Phillips AN; Francioli P; Vanhems P; Egger M; Rickenbach M; Cooper D; Kaldor J; Ashton L; Vizzard J; Muga R; Day NE; De Angelis D;
    Int J Epidemiol; 2002 Oct; 31(5):951-8. PubMed ID: 12435766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study.
    Prins M; Veugelers PJ
    AIDS; 1997 Apr; 11(5):621-31. PubMed ID: 9108944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of disease progression in HIV-infected homosexual men with CD4+ cells < 200 x 10(6)/l but free of AIDS-defining clinical disease.
    Keet IP; Krol A; Koot M; Roos MT; de Wolf F; Miedema F; Coutinho RA
    AIDS; 1994 Nov; 8(11):1577-83. PubMed ID: 7848594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study.
    Cozzi Lepri A; Sabin CA; Phillips AN; Lee CA; Pezzotti P; Rezza G
    Epidemiol Infect; 1998 Oct; 121(2):369-76. PubMed ID: 9825787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II.
    AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
    Bhaskaran K; Mussini C; Antinori A; Walker AS; Dorrucci M; Sabin C; Phillips A; Porter K;
    Ann Neurol; 2008 Feb; 63(2):213-21. PubMed ID: 17894380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
    Clements M; Law M; Pedersen C; Kaldor J;
    HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.